Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Mini-Review Article

Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents

In Press, (this is not the final "Version of Record"). Available online 07 June, 2024
Author(s): Elena Martino*, Shruti Thakur, Arun Kumar, Ashok Kumar Yadav, Donatella Boschi, Deepak Kumar and Marco Lolli
Published on: 07 June, 2024

DOI: 10.2174/0113895575303614240527093106

Price: $95

Abstract

Cancer remains a primary cause of death globally, and effective treatments are still limited. While chemotherapy has notably enhanced survival rates, it brings about numerous side effects. Consequently, the ongoing challenge persists in developing potent anti-cancer agents with minimal toxicity. The versatile nature of the quinazoline moiety has positioned it as a pivotal component in the development of various antitumor agents, showcasing its promising role in innovative cancer therapeutics. This concise review aims to reveal the potential of quinazolines in creating anticancer medications that target histone deacetylases (HDACs).

Keywords: Quinazoline, HDAC inhibitors, cancer, anti-proliferative agents, hybrid HDAC inhibitors, multitarget approach


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy